Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

MiraKind · NCT02253251

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
15000
US sites recruiting
1
Study start
September 2014
Record last updated
January 23, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Being studied: KRAS-variant and microRNA binding site mutation testing

Conditions: Cancer

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Personal or family history of cancer
  • Personal history of endometriosis, or autoimmunity

Exclusion Criteria

  • Younger than 18
  • Non-english speaking and unable to understand and sign the consent

Recruiting US locations

  • MiraKind

    Los Angeles, CA 90025

    Site contact: Joanne Weidhaas, MDPhD · 203-671-1308 · joanne@mirakind.org

Study contacts (from the official record)

  • Joanne Weidhaas, MDPhD · 203-671-1308 · joanne@mirakind.org
  • Joanne Weidhaas · 424-387-8100 · Joanne@miradx.com
All women’s health studies in California →
Clinical Validation of the Role of microRNA Binding Site Mutations… (NCT02253251) | Bored Studies